.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Details for Patent: 7,323,479

« Back to Dashboard

Details for Patent: 7,323,479

Title:Methods for treatment and management of brain cancer using 1-oxo-2-(2,6-dioxopiperidin-3-yl)-4-methylisoindoline
Abstract: Methods of treating, preventing and/or managing cancer as well as and diseases and disorders associated with, or characterized by, undesired angiogenesis are disclosed. Specific methods encompass the administration of an immunomodulatory compound alone or in combination with a second active ingredient. The invention further relates to methods of reducing or avoiding adverse side effects associated with chemotherapy, radiation therapy, hormonal therapy, biological therapy or immunotherapy which comprise the administration of an immunomodulatory compound. Pharmaceutical compositions, single unit dosage forms, and kits suitable for use in methods of the invention are also disclosed.
Inventor(s): Zeldis; Jerome B. (Princeton, NJ)
Assignee: Celgene Corporation (Summit, NJ)
Filing Date:Nov 06, 2003
Application Number:10/704,237
Claims:1. A method of treating brain cancer which comprises administering to a patient having brain cancer about 0.1 to about 150 mg per day of 1-oxo-2-(2,6-dioxopiperidin-3-yl)-4-methylisoindoline represented by the formula: ##STR00024## or a pharmaceutically acceptable salt, solvate or stereoisomer thereof.

2. The method of claim 1, wherein the compound is 1-oxo-2-(2,6-dioxopiperidin-3-yl)-4-methylisoindoline.

3. The method of claim 1, wherein the compound is a pharmaceutically acceptable salt.

4. The method of claim 1, wherein the compound is a pharmaceutically acceptable solvate.

5. The method of claim 1, wherein the compound is a pharmaceutically acceptable stereoisomer.

6. The method of claim 5, wherein the stereoisomer is an enantiomerically pure R isomer.

7. The method of claim 5, wherein the stereoisomer is an enantiomerically pure S isomer.

8. The method of claim 1, wherein the brain cancer is neuroblastoma, meningioma, hemangiopericytoma, glioblastoma, brain stem glioma, malignant glioma, anaplastic astrocytoma, or anaplastic oligodendroglioma.

9. The method of claim 8, wherein the brain cancer is glioblastoma multiform.

10. The method of claim 8, wherein the brain cancer is poor prognosis malignant brain tumor.

11. The method of claim 1, which further comprises administering a therapeutically effective amount of a second active agent selected from the group consisting of hematopoietic growth factor, a cytokine and an anti-cancer agent.

12. The method of claim 11, wherein the second active agent is temozolomide, and the patient has relapsed or progressive brain tumor, or recurrent neuroblastoma.

13. The method of claim 11, wherein the second active agent is celecoxib, etoposide or cyclophosphamide, and the patient has relapsed or progressive brain tumor.

14. The method of claim 11, wherein the second active agent is temodar, and the patient has recurrent or progressive meningioma, malignant meningioma, hemangiopericytoma, relapsed brain tumor, or newly diagnosed glioblastoma multiform.

15. The method of claim 11, wherein the second active agent is irinotecan, and the patient has recurrent glioblastoma.

16. The method of claim 11, wherein the second active agent is carboplatin, and the patient has brain stem glioma.

17. The method of claim 11, wherein the second active agent is procarbazine, and the patient has progressive malignant glioma.

18. The method of claim 11, wherein the second active agent is cyclophosphamide, and the patient has poor prognosis malignant brain tumor, newly diagnosed or recurrent glioblastoma multiform.

19. The method of claim 11, wherein the second active agent is carmustine, and the patient has high grade recurrent malignant glioma.

20. The method of claim 11, wherein the second active agent is temozolomide or tamoxifen, and the patient has anaplastic astrocytoma.

21. The method of claim 11, wherein the second active agent is topotecan, and the patient has glioma, glioblastoma, anaplastic astrocytoma or anaplastic oligodendroglioma.

22. The method of claim 1, which further comprises administering radiation therapy, hormonal therapy, biological therapy or immunotherapy.

23. The method of claim 1, wherein the compound is administered orally.

24. The method of claim 1, wherein the compound is administered in the form of a capsule or tablet.

25. The method of claim 1, wherein the compound is administered cyclically.

26. The method of claim 1, wherein one cycle comprises four to six weeks.

27. The method of claim 1, wherein one cycle comprises the administration of the compound for 21 days followed by seven days rest.

28. The method of claim 25, wherein the compound is administered for four to twenty-four weeks with one to six weeks of rest.

29. The method of claim 25, wherein the compound is administered in an amount of from about 0.1 to about 150 mg per day for 21 days every 28 days for sixteen to twenty-four weeks.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

How are People Using DrugPatentWatch?

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc